ID   PC-9/CDDP
AC   CVCL_ZZ72
DR   cancercelllines; CVCL_ZZ72
DR   Wikidata; Q102114750
RX   PubMed=17237272;
RX   PubMed=18445659;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B260 ! PC-9
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 05-10-23; Version: 6
//
RX   PubMed=17237272; DOI=10.1158/1535-7163.MCT-06-0529;
RA   Oguri T., Bessho Y., Achiwa H., Ozasa H., Maeno K., Maeda H., Sato S.,
RA   Ueda R.;
RT   "MRP8/ABCC11 directly confers resistance to 5-fluorouracil.";
RL   Mol. Cancer Ther. 6:122-127(2007).
//
RX   PubMed=18445659; DOI=10.1158/1535-7163.MCT-07-2088;
RA   Oguri T., Ozasa H., Uemura T., Bessho Y., Miyazaki M., Maeno K.,
RA   Maeda H., Sato S., Ueda R.;
RT   "MRP7/ABCC10 expression is a predictive biomarker for the resistance
RT   to paclitaxel in non-small cell lung cancer.";
RL   Mol. Cancer Ther. 7:1150-1155(2008).
//